Select a medication above to begin.
Adzynma (ADAMTS13, recombinant-krhn)
ADAMTS13, recombinant
Adult Dosing .
Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = ADAMTS13, recombinant-krhn
thrombotic thrombocytopenic purpura, congenital
- [prophylaxis regimen]
- Dose: 40 IU/kg/dose IV q2wk; Info: may incr. frequency to qwk based on prior regimen or clinical response
- [on-demand regimen]
- Dose: 40 IU/kg/dose IV x1 on day 1, then 20 IU/kg/dose IV x1 on day 2, then 15 IU/kg/dose IV qd starting day 3 until 2 days after acute event resolved
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Peds Dosing .
- Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = ADAMTS13, recombinant-krhn
thrombotic thrombocytopenic purpura, congenital
- [prophylaxis regimen, 2 yo and older]
- Dose: 40 IU/kg/dose IV q2wk; Info: may incr. frequency to qwk based on prior regimen or clinical response
- [on-demand regimen, 2 yo and older]
- Dose: 40 IU/kg/dose IV x1 on day 1, then 20 IU/kg/dose IV x1 on day 2, then 15 IU/kg/dose IV qd starting day 3 until 2 days after acute event resolved
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
Drug Interactions .
Overview
ADAMTS13, recombinant
ADAMTS13 enzyme replacement
-
None
No significant interactions known or found for this drug. Caution always advised with multiple medications.
Adverse Reactions .
Serious Reactions
- anaphylaxis
- hypersensitivity reaction
Common Reactions
- headache
- diarrhea
- migraine
- abdominal pain
- nausea
- URI
- dizziness
- vomiting
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available; no known risk of fetal harm based on animal data up to 10x recommended human dose
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: other; Half-life: 30.1-90.8h (patients 12 yo and older)
Subclass: Anti-von Willebrand Factors
Mechanism of Action
recombinant A disintegrin and metalloproteinase with thrombospondin motifs 13 (rADAMTS13) cleaves large and ultra-large von Willebrand factor (VWF) multimers; reducing platelet binding and microthrombi formation
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.